8-K Summary
Business Context and Reporting Period
Cullinan Oncology, Inc. (now identified in the request metadata as Cullinan Therapeutics, Inc.) filed a Form 8-K dated May 17, 2021, under Item 5.02 regarding a change in executive leadership. The company is a Delaware corporation listed on Nasdaq under the symbol CGEM.
Executive Change and Compensation
- Jon Wigginton, M.D. resigned as Chief Medical Officer effective May 20, 2021.
- The filing states that the resignation was not related to any disagreement with the company, its board, operations, policies, or practices.
- Dr. Wigginton entered into a consulting agreement effective May 20, 2021, to provide advisory services as mutually agreed with the company.
- He will also serve as Chair of the company’s Scientific Advisory Board.
- Consulting compensation is $31,250 per month.
- Equity awards held by Dr. Wigginton as of the effective date will continue to vest during the consulting agreement term.
Financial Metrics, Outlook, and Risks
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, guidance, or other operating and financial metrics. It also does not identify specific contingencies or unusual financial items.
Most Important Facts to Verify
- The effective date of Dr. Wigginton’s resignation and consulting arrangement: May 20, 2021.
- The monthly consulting payment of $31,250 and continued vesting of existing equity awards.
- The scope and duration of the consulting agreement, which are not fully detailed in the filing text.
- The company’s subsequent appointment or designation of a permanent Chief Medical Officer.